Korean J Med.
2024 Apr;99(2):61-68. 10.3904/kjm.2024.99.2.61.
Sodium-Glucose Cotransporter 2 Inhibitors for Chronic Kidney Disease: A Comprehensive Review
- Affiliations
-
- 1Division of Nephrology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
- KMID: 2554305
- DOI: http://doi.org/10.3904/kjm.2024.99.2.61
Abstract
- Chronic Kidney Disease (CKD) is a major global health burden. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated potential in slowing CKD progression. We evaluated the expanding role of SGLT2 inhibitors, emphasizing their renoprotective benefits in diabetic and non-diabetic CKD patients. We also investigated the underlying mechanisms, including the reduction of glomerular hypertension via modulation of tubuloglomerular feedback. Our study critically analyzed current indications for SGLT2 inhibitor therapy based on recent clinical trial data. To optimize patient outcomes, we present a comprehensive analysis of practical considerations for the prescription of SGLT2 inhibitors, including the potential initial decline in the estimated glomerular filtration rate and a review of adverse events.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Glucose Lowering Effect of SGLT2 Inhibitors: A Review of Clinical Studies
- SGLT2 Inhibitors and Ketoacidosis: Pathophysiology and Management
- Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
- Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
- Sodium-Glucose Cotransporter 2 Inhibitors: Mechanisms of Action and Various Effects
